| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8486458 | Vaccine | 2017 | 6 Pages |
Abstract
All dose levels were considered safe and well tolerated. There was a statistically significant increase in anti-PnuBioVax IgG titres at the 200 and 500 µg dose levels compared to 50 µg and placebo. Trial registration number: NCT02572635https://www.clinicaltrials.gov.
Keywords
MedDRATEAEsMesoScale DiscoveryPsaAPspAMSDECLEPTTMBIPD3,3′,5,5′-tetramethylbenzidineAesElectrochemiluminescencestandard deviationOtitis mediaSafetyImmunogenicityPIAAInvasive pneumococcal diseaseEnzyme-linked immunosorbent assayELISAMedical Dictionary for Regulatory ActivitiesPneumococcal infectionAdverse eventsPhase IPLYwild typePCV یا Pneumococcal conjugate vaccinePneumococcal surface protein APneumolysin
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Claire Entwisle, Sue Hill, Yin Pang, Michael Joachim, Ann McIlgorm, Camilo Colaco, David Goldblatt, Polly De Gorguette D'Argoeuves, Chris Bailey,